What are the key takeaways from this Pathfinders in Biopharma episode?

Key insights include: **NLRP3 Inflammasome Targeting:** Chronic inflammation rises with age and drives metabolic disease, including obesity. BioAge's brain-penetrant NLRP3 inhibitors, entering clinical trials in 2025, aim to suppress neuroinflammation that disrupts appetite regulation—offering a potential intervention earlier in disease progression than current treatments address.; **Exercise Biology as Drug Discovery:** Apelin, a circulating blood factor that declines with age but surges during exercise, represents a class of "exerkines" that can be mimicked therapeutically. BioAge's Novartis partnership targets this biology to identify metabolic and neurological drug candidates modeled on exercise's proven physiological benefits.; **Centenarian Data as Target Validation:** Studying people who live past 100 in good physical and cognitive health reveals molecular differences that validate drug targets. CETP inhibitors, for example, were identified partly because centenarians carry natural loss-of-function mutations in that gene—providing human genetic proof before clinical development.

What did Kristin Fortney discuss on Pathfinders in Biopharma?

BioAge CEO Kristen Fortney explains how studying centenarian biology and aging pathways—including NLRP3 inflammation and exercise-mimicking compounds like apelin—drives drug discovery targeting metabolic and age-related diseases. Key topics include: **NLRP3 Inflammasome Targeting:** Chronic inflammation rises with age and drives metabolic disease, including obesity. BioAge's brain-penetrant NLRP3 inhibitors, entering clinical trials in 2025, aim to suppress neuroinflammation that disrupts appetite regulation—offering a potential intervention earlier in disease progression than current treatments address.; **Exercise Biology as Drug Discovery:** Apelin, a circulating blood factor that declines with age but surges during exercise, represents a class of "exerkines" that can be mimicked therapeutically. BioAge's Novartis partnership targets this biology to identify metabolic and neurological drug candidates modeled on exercise's proven physiological benefits..

How long is this episode of Pathfinders in Biopharma?

This episode is 19 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Pathfinders in Biopharma

BioAge is translating insights from the science of aging into new medicines

May 29, 2025

19 min episode · 2 min read

Kristin Fortney

Episode

19 min

Read time

2 min

Topics

Health & Wellness, Relationships, Investing

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓NLRP3 Inflammasome Targeting: Chronic inflammation rises with age and drives metabolic disease, including obesity. BioAge's brain-penetrant NLRP3 inhibitors, entering clinical trials in 2025, aim to suppress neuroinflammation that disrupts appetite regulation—offering a potential intervention earlier in disease progression than current treatments address.
✓Exercise Biology as Drug Discovery: Apelin, a circulating blood factor that declines with age but surges during exercise, represents a class of "exerkines" that can be mimicked therapeutically. BioAge's Novartis partnership targets this biology to identify metabolic and neurological drug candidates modeled on exercise's proven physiological benefits.
✓Centenarian Data as Target Validation: Studying people who live past 100 in good physical and cognitive health reveals molecular differences that validate drug targets. CETP inhibitors, for example, were identified partly because centenarians carry natural loss-of-function mutations in that gene—providing human genetic proof before clinical development.
✓Sarcopenia Regulatory Gap: No FDA approval pathway currently exists for sarcopenia or frailty, despite measurable endpoints and large patient populations. Establishing this path—as the EMA and Japan are exploring given aging demographics—could unlock a significant pipeline of muscle-preserving therapies and accelerate investment in aging indications.

What It Covers

BioAge CEO Kristen Fortney explains how studying centenarian biology and aging pathways—including NLRP3 inflammation and exercise-mimicking compounds like apelin—drives drug discovery targeting metabolic and age-related diseases.

Key Questions Answered

•NLRP3 Inflammasome Targeting: Chronic inflammation rises with age and drives metabolic disease, including obesity. BioAge's brain-penetrant NLRP3 inhibitors, entering clinical trials in 2025, aim to suppress neuroinflammation that disrupts appetite regulation—offering a potential intervention earlier in disease progression than current treatments address.
•Exercise Biology as Drug Discovery: Apelin, a circulating blood factor that declines with age but surges during exercise, represents a class of "exerkines" that can be mimicked therapeutically. BioAge's Novartis partnership targets this biology to identify metabolic and neurological drug candidates modeled on exercise's proven physiological benefits.
•Centenarian Data as Target Validation: Studying people who live past 100 in good physical and cognitive health reveals molecular differences that validate drug targets. CETP inhibitors, for example, were identified partly because centenarians carry natural loss-of-function mutations in that gene—providing human genetic proof before clinical development.
•Sarcopenia Regulatory Gap: No FDA approval pathway currently exists for sarcopenia or frailty, despite measurable endpoints and large patient populations. Establishing this path—as the EMA and Japan are exploring given aging demographics—could unlock a significant pipeline of muscle-preserving therapies and accelerate investment in aging indications.

Notable Moment

Fortney notes that FGF21, now among the most commercially valuable drug targets via incretins, has long appeared in aging biology research—transgenic mice with elevated FGF21 live roughly 30% longer—suggesting the field's most lucrative targets may already exist in plain sight.

Know someone who'd find this useful?